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Abstract
Predicting the survival time of a cancer patient based on his/her genome-wide gene expression re-
mains a challenging problem. For certain types of cancer, the effects of gene expression on survival
are both weak and abundant, so identifying nonzero effects with reasonable accuracy is difficult. As an
alternative to methods that use variable selection, we propose a Gaussian process accelerated failure time
model to predict survival time using genome-wide or pathway-wide gene expression data. Using a Monte
Carlo EM algorithm, we jointly impute censored log-survival time and estimate model parameters. We
demonstrate the performance of our method and its advantage over existing methods in both simulations
and real data analysis. The real data that we analyze were collected from 513 patients with kidney renal
clear cell carcinoma and include survival time, demographic/clinical variables, and expression of more
than 20,000 genes. Our method is widely applicable as it can accommodate right, left, and interval cen-
sored outcomes; and provides a natural way to combine multiple types of high-dimensional -omics data.
An R package implementing our method is available for download at github.com/ajmolstad/SurvGPR.
Keywords: survival time, gene expression, Gaussian process accelerated failure time model, multiple
kernel learning
1 Introduction
Predicting the survival time of a cancer patient based on his/her genome-wide gene expression is a well
studied, yet unresolved problem. In some types of cancer, the effects of gene expression are both weak and
abundant which, when combined with often high censoring rates, makes feature selection for survival time
association very challenging. On the other hand, genome-wide gene expression data can be highly informa-
tive for prognosis. For example, Zhu et al. (2017) demonstrate that two patients with similar genome-wide
gene expression data may have similar survival time.
Our method development is motivated by a dataset with genome-wide gene expression, survival time,
and some demographical/clinical variables of more than 500 patients with kidney renal clear cell carcinoma,
which is part of The Cancer Genome Atlas (TCGA) project (http://cancergenome.nih.gov/). To demonstrate
that the associations between gene expression and survival time are abundant and weak in this dataset, we
first report results of gene-by-gene marginal association testing. For each gene, we fit two Cox proportional
∗Correspondence: wsun@fredhutch.org
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Figure 1: Histograms of the marginal p-values for each of the 20,483 genes for (a): Model I and (b): Model
II. Histograms of the concordance for each of the 20,483 marginal models for (c): Model I and (d): Model
II. Dark dotted lines in (c) and (d) denote the concordance measurement of survival time prediction under
the baseline model that includes all the covariants in Model I or II, other than gene expression.
hazards models. In Model I, we include only the expression of this gene as a predictor and the sequencing
plate ID as a confounder. In Model II, we include the expression of this gene, sequencing plate ID, and three
demographical/clinical covariates: age, gender, and tumor stage. Histograms of the marginal p-values are
displayed in Figure 1(a) and (b).
Assuming genes with p-value larger than 0.5 are not associated with survival time, we can calculate the
expected number of genes associated with survival time by p(1 − 2s/p), where s is the number of genes
with p-value > 0.5 and p = 20, 483 is the total number of genes. This number is 13,052 and 10,512 for
Models I and II, respectively. Similarly, with a false discovery rate of 0.05, the number of genes that are
significantly associated with survival time are 8,550 and 4,312 for Models I and II, respectively. The large
number of genes associated with survival time is biologically plausible given that kidney renal clear cell
carcinoma is characterized by oncogenic metabolism and epigenetic reprogramming, both of which may
affect the expression of many genes (Cancer Genome Atlas Research Network, 2013).
In Figures 1(c) and (d), we display the survival time prediction concordances (C-index) for the 20,483
2
marginal models. The dark dashed vertical lines denote the concordance of the baseline model, i.e., the
model excluding gene expression but including sequencing plate ID (Model I) as well as clinical covariates
(Model II). For Model I, including a single gene can improve concordance by as much as six percent.
Comparatively, the improvement in concordance for Model II is smaller, with a single gene improving
concordance no more than two percent. The concordance improvements indicate that gene expression can
improve the prediction of survival time, although few, if any, genes appear to have strong effects. Together,
these results suggest that screening or variable selection may be difficult or ineffective because of potentially
weak and abundant effects.
In our proposed method, we do not attempt to identify a subset of genes associated with survival time.
Instead, we use genome-wide gene expression to model the covariance of the log-survival time under a
Gaussian process accelerated failure time model. Inspired by multiple kernel learning (Go¨nen and Alpaydın,
2011), we allow the covariance to be a linear combination of M user-specified candidate kernels. A major
challenge for survival time prediction is censoring. To mitigate this challenge, we develop an efficient Monte
Carlo EM algorithm which jointly imputes censored log-survival times and estimates model parameters. The
imputed survival times are then used in our subsequent prediction rule.
The majority of methods for survival time prediction address censoring using partial likelihood methods,
which use event orderings rather than the times at which they occur. Consequently, when survival time can be
predicted with reasonable accuracy, partial likelihood methods may miss useful information in the censoring
times. Alternatively, some methods use a two-step approach to first impute censored survival times (e.g.,
mean, median, or multiple imputation), and then fit a predictive model using the imputed survival times
(Datta et al., 2007; Wu et al., 2008).
Some other methods iteratively impute the censored survival times and fit a predictive model, for exam-
ple, using survival trees (Zhu and Kosorok, 2012) or an ensemble model (Deng et al., 2016). These methods
were not designed for ultra-high dimensional -omic data. For example, in their real data analysis examples,
the sample size (n) and the number of covariates (p) are n = 686 and p = 8 for Zhu and Kosorok (2012),
and n = 2070 and p = 256 for Deng et al. (2016). In contrast, we propose a new method that iteratively
imputes the censored survival times and fits a kernel-based predictive model. Our real data analysis has
much higher dimensionality than the earlier methods with n = 513 and p = 20, 428. Zhu et al. (2017) also
employed a kernel-based method for survival time prediction using gene expression, though they only used
one kernel derived from gene expression and did not seek to impute the censored survival times.
The remainder of this article is organized as follows: in Section 2 we described our proposed model and
discuss its relation to existing methods; in Section 3 we describe how to compute our estimator; in Section 4
we perform simulation studies to demonstrate our method’s prediction accuracy under a range of models; in
Section 5 we analyze the TCGA dataset which motivated our study; and in Section 6 we discuss limitations
and extensions of our method.
3
2 Gaussian process accelerated failure time model
Let Si denote the time-to-failure (survival time) for the ith patient with i = 1, . . . , n patients in the study.
Let T = (logS1, . . . , logSn)′ ∈ Rn. Let xi ∈ Rp and zi ∈ Rq+1 denote the measured genome-wide gene
expression and the measured clinical variables for the ith patient, respectively. To allow for an intercept,
assume that the first entry of zi is equal to one for i = 1, . . . , n. Let Z = (z1, . . . , zn)′ ∈ Rn×(q+1), and
X = (x1, . . . , xn)
′ ∈ Rn×p. For the n patients in the study, we assume that survival time follows the
Gaussian process accelerated failure time model:
T = Zβ +G+ , G ∼ Nn
{
0,K(X,σ2)
}
,  ∼ Nn
{
0, σ2 In
}
, (1)
where G and  are independent; σ2 ∈ RM+ , σ2 ∈ R+, and β ∈ Rq+1 are unknown model parameters,
R+ denotes non-negative real numbers, and M is the number of kernels. We will sometimes use the more
compact notation: Cov(G+ ) ≡ K˜(X, σ˜2) = K(X,σ2) + σ2 In, where σ˜2 = (σ2′, σ2 )′ ∈ RM+1+ .
The function K : Rn×p × RM+ → Sn+ is a covariance function with (i, j)th entry
[K(X,σ2)]i,j =
M∑
s=1
σ2sks(xi, xj), (i, j) ∈ {1, . . . , n} × {1, . . . , n} ,
where Sn+ denotes the set of n × n symmetric and positive definite matrices, and ks : Rp × Rp → R
is a positive definite kernel function for s = 1, . . . ,M . A positive definite kernel function ensures that
the matrix ks(X,X): Rn×p × Rn×p → Sn+, whose (i, j)th entry is ks(xi, xj), is positive definite for all
X ∈ Rn×p. The function ks(xi, xj) quantifies the similarity between xi and xj , e.g., a radial basis kernel
function is ks(xi, xj) = exp(−‖xi − xj‖2).
The Gaussian process accelerated failure time model in (1) generalizes the log-normal accelerated failure
time model of Klein et al. (1999), which for clustered subjects, assumed that Cov(Ti, Tj) = φ for all (i, j)
such that i and j belong to the same cluster and i 6= j. Gaussian processes have also been used for survival
analysis under the Cox proportional hazards model (Banerjee et al., 2003; Ferna´ndez et al., 2016; Zhu et al.,
2017). Intuitively, (1) assumes that if two patients have similar genome-wide gene expression, as defined
by K, then their mean-adjusted log-survival times will be similar. Out-of-sample prediction based on (1)
is also known as kriging, a method for prediction through linear interpolation in geo-spatial statistics. In
geo-spatial applications, the function K is used to quantify the similarities of two-dimensional coordinates,
whereas in our application, K quantifies similarities in an ultra-high dimensional, genome-wide space.
Recently, kriging was applied in the genomic literature as a means for predicting a phenotypic trait using
multiple types of -omics data (Wheeler et al., 2014).
Fitting (1) is non-trivial when one observes a censored realization of T , as is often the case in survival
analysis. Specifically, suppose there exists a realization T = (t1, . . . , tn)′ ∈ Rn, which cannot be observed.
Instead one observes the pairs (y1, δ1), . . . , (yn, δn) where yi = min(ti, di), di is the censoring time for
the ith subject, δi = 1(yi = ti) for i = 1, . . . , n, and 1(·) is an indicator function. In this article, we treat
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the censored survival times as missing. This allows us to develop an algorithm that simultaneously imputes
the latent survival times conditional on the observed survival times and model parameters; and estimates
model parameters β,σ2, σ2 . Although we focus on the case of right-censored outcomes, our methodology
naturally accommodates right, left, and interval censoring.
For the remainder of the article, without loss of generality, suppose that δi = 0 for i = 1, . . . , nc,
δi = 1 for i = nc + 1, . . . , n, and let no = n − nc. Hence, we can partition Y = (y1, . . . , yn)′ into
Yc ∈ Rnc and Yo ∈ Rno so that Y = (Y ′c , Y ′o)′ ∈ Rn. We similarly partition T into (T ′c, T ′o)′ (where Tc is
not observed and To = Yo); Z into Zc ∈ Rnc×(q+1) and Zo ∈ Rno×(q+1); and K˜(X, σ˜2) into sub-matrices
K˜co(X, σ˜
2) ∈ Rnc×no , K˜oo(X, σ˜2) ∈ Rno×no , and K˜cc(X, σ˜2) ∈ Rnc×nc . For ease of display, we will
sometimes omit the (X, σ˜2) dependence on K˜(X, σ˜2) and its submatrices. Let H = Rq+1 × RM+ × R+
denote the space of the unknown parameters θ = (β′,σ2, σ2 )′. Finally, let W be the collection of data that
we condition on: W = {Z,X, Y, δ}.
3 Maximum likelihood estimation
3.1 Overview
To fit the Gaussian process accelerated failure time model in (1), we use a Monte Carlo expectation-
maximization (MC-EM) algorithm. We provide an overview of the MC-EM algorithm in Section 3.2 and
describe the sub-algorithms used for distinct covariance function specifications in Section 3.3. We imple-
ment our MC-EM algorithm, along with a set of auxiliary functions, in ab R package SurvGPR, which is
available in the Supplementary Materials.
3.2 Monte Carlo expectation-maximization algorithm
Throughout this section, let the superscript (r) denote the rth iterate of the MC-EM algorithm, and let sr
denote the rth iterate’s Monte Carlo sample size.
The (r+1)th iterate of the standard expectation-maximization (EM) algorithm is computed in two steps:
the E-step computes
Q(θ | θ(r)) = E
[
log fT (To, Tc; θ,W ) | θ(r),W
]
, (2)
where log fT is the log-likelihood of T ; and the M-step computes
θ(r+1) = arg max
θ∈H
Q(θ | θ(r)). (3)
When (3) cannot be obtained, an alternative is to compute θ(r+1) such that
θ(r+1) ∈
{
θ ∈ H : Q(θ | θ(r)) ≥ Q(θ(r) | θ(r))
}
, (4)
which yields the generalized EM algorithm (Wu et al., 1983).
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Unfortunately, when log-survival times are censored, there may not exist an analytic expression for the
right hand side of (2) under (1). In particular, ignoring constants,
Q(θ | θ(r)) ∝ −E
[
log det{K˜(X, σ˜2)}+ (T − Zβ)′{K˜(X, σ˜2)}−1(T − Zβ) | θ(r),W
]
, (5)
so that computing Q(θ | θk) requires evaluating
(i) E
[
Tc | θ(r),W
]
, (ii) E
[
T ′c(K˜cc − K˜coK˜−1oo K˜ ′co)−1Tc | θ(r),W
]
.
Computing (i) and (ii) is non-trivial because
Tc | θ(r),W ∼ N[Yc,∞)nc
{
Zcβ
(r) + K˜coK˜
−1
oo (To − Zoβ(r)), K˜cc − K˜coK˜−1oo K˜ ′co
}
, (6)
where the notation N[Yc,∞)nc denotes the nc-dimensional truncated multivariate normal distribution with
nonzero probability mass on the hyper-rectangle [Yc,∞) = [y1,∞) × · · · × [ync ,∞). Although (i) can
be computed numerically, the distribution of (K˜cc− K˜coK˜−1oo K˜ ′co)−1/2Tc | (θ(r),W ) is not truncated multi-
variate normal unless (K˜c − K˜coK˜−1oo K˜ ′co) = Inc (Horrace, 2005), so (ii) is intractable in general. Instead,
we approximate (2) by drawing sr samples from (6) (Wei and Tanner, 1990).
There are multiple software packages available to simulate from (6). In our implementation, we use
the Gibbs sampler implemented in the tmvtnorm package in R (Wilhelm and Manjunath, 2015). Let
T˜
(r)
c = (T
(r)
c,1 , . . . , T
(r)
c,sr)
′ ∈ Rsr×nc be the matrix of samples from (6). Given T˜ (r)c , the (r + 1)th iterate of
our MC-EM algorithm is
θ(r+1) = arg max
θ∈H
s−1r
sr∑
j=1
log fT (To, T
(r)
c,j ; θ,W )
 . (7)
We propose an algorithm to compute (7) in Section 3.3. To improve the efficiency of our MC-EM algorithm,
we use the ascent-based variation proposed by Caffo et al. (2005). We state our complete ascent-based MC-
EM algorithm in Algorithm 1.
Algorithm 1: Initialize θ(1) = (β(1),σ2(1), σ2(1) ). Set r = 1 and s1 = 500.
1. Simulate T˜ (r)c , sr samples from
N[Yc,∞)nc
{
Zcβ
(r) + K˜ ′coK˜
−1
oo (To − Zoβ(r)), K˜cc − K˜coK˜−1oo K˜oc
}
.
2. Compute θ¯ ← arg maxθ∈H
{
s−1r
∑sr
j=1 log fT (To, T
(r)
c,j ; θ,W )
}
.
3. Compute ASE(r), the standard error of
{
log fT (To, T
(r)
c,j ; θ¯,W )− log fT (To, T (r)c,j ; θ(r),W )
}sr
j=1
.
4a. If s−1r
∑sr
j=1
{
log fT (To, T
(r)
c,j ; θ¯,W )− log fT (To, T (r)c,j ; θ(r),W )
}
> 1.96ASE(r)
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– Set θ(r+1) ← θ¯, sr+1 = sr, r ← r + 1, and return to Step 1.
4b. Else
– If sr ≥ 105, terminate. Else, set sr ← 2sr and return to Step 1, appending sr new samples
to the sr from the previous iteration.
We terminate the algorithm based on a Monte Carlo sample size threshold in Step 4. When the algorithm
has converged, the difference between θ(r) and θ¯ will be negligible for sufficiently large sr. In practice, we
suggest practitioners track the parameter estimates across iterations to ensure that 105 is a sufficiently large
threshold for their application.
Because we use a Gibbs sampler in Step 1, the simulated T (r)c,j may be correlated. To decrease de-
pendence while maintaining computational efficiency, we keep every tenth sample generated by the Gibbs
sampler (Owen, 2017). To compute the standard error in Step 3 while accounting for the serial correlations
due to the Gibbs sampler, we use the spectral variance method with a Tukey-Hanning window implemented
in the R package mcmcse (Flegal et al., 2017).
3.3 Maximization algorithms
We now describe how to solve Step 2 of Algorithm 1. Throughout this section, treat r as fixed, let Tˆj =
(T
(r)′
c,j , T
′
o) for j = 1, . . . , sr, and let T¯ = s
−1
r
∑sr
j=1 Tˆj . We develop distinct algorithms for solving (7) for
two types of covariance functions: the single kernel case (M = 1), and the more general case of multiple
distinct kernel functions (M ≥ 1). For both cases, we solve (7) using blockwise coordinate descent. The
algorithm we use for the case that M = 1 is described in the Supplementary Material. This algorithm
exploits that k1(X,X) and K˜(X, σ˜2) have the same eigenvectors under (1).
For the general case that M ≥ 1, we use a variation of the blockwise coordinate descent algorithm
proposed by Zhou et al. (2015). The complete algorithm is stated in Algorithm 2.
Algorithm 2: Initialize θ(1) = (β(1),σ2(1), σ2(1) ) at their final iterates from the previous M-step. Set
b = 1.
1. Compute Ω← K˜(X, σ˜2(b))−1
2. Compute β(b+1) ← (Z ′ΩZ)−1Z ′ΩT¯
3. For i = 1, . . . ,M, compute
σ
2(b+1)
i ←
σ
2(b)
i√
sr
[∑sr
j=1(Tˆj − Zβ(b+1))′Ω′ki(X,X)Ω(Tˆj − Zβ(b+1))
tr {Ωki(X,X)}
]1/2
,
4. Compute
σ2(b+1) ←
σ
2(b)
√
sr
[∑sr
j=1(Tˆj − Zβ(b+1))′Ω′Ω(Tˆj − Zβ(b+1))
tr(Ω)
]1/2
.
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5a. If {∑srj=1 log fT (To, T (r)c,j ; θ(b+1),W )− log fT (To, T (r)c,j ; θ(b),W )}
≤ |∑srj=1 fT (To, T (r)c,j ; θ(1),W )|
– Terminate.
5b. Else
– Set b← b+ 1 and return to Step 1.
The updates of σ2(b+1)i and σ
2(b+1)
 in Steps 3 and 4 are derived based on the minorize-maximize (MM)
algorithm for variance components estimation proposed by Zhou et al. (2015). Briefly, given the initial
values of the parameters or their estimates from the previous iteration, a minorizing function is created
to approximate the objective function. The updates in Steps 3 and 4 are the arguments that maximize
a minorizing function and thus, ensure that the objective function evaluated at θ(b+1) is greater than or
equal to the objective function evaluated at θ(b). A complete derivation of Algorithm 2 is provided in the
Supplementary Material.
In our implementation, we also use quasi-Newton-like acceleration attempts based on an extrapolation
heuristic. We found that the iterates from Steps 3 and 4 of Algorithm 2 often followed monotonic paths to
their local maximizers. Thus, after Step 4, we attempt to replace σ2(b+1) with an extrapolated value
σ¯2(b+1) = σ2(b+1) + (b1/2 + 2)−1(σ2(b+1) − σ2(b)),
and similarly for σ2(b+1) . If the log-likelihood evaluated at the extrapolated values σ¯2(b+1) and σ¯
2(b+1)
 is
greater than the log-likelihood evaluated at the σ2(b+1) and σ2(b+1) , we replace σ2(b+1) with σ¯2(b+1) and
σ
2(b+1)
 with σ¯
2(b+1)
 .
3.4 Implementation and practical considerations
Given the final iterates of the MC-EM algorithm, βˆ, σˆ2, σˆ2 , and final imputed survival time, T¯ , we pre-
dict log-survival time for a new patient with covariates z∗ and genome-wide gene expression x∗ using the
conditional expectation of the univariate normal distribution:
N
{
βˆ
′
z∗ +K∗(x∗, X, σˆ2)′K˜(X, ˆ˜σ2)−1(T¯ − Zβˆ), K˜(x∗, ˆ˜σ2)−K∗(x∗, X, σˆ2)′K˜(X, ˆ˜σ2)−1K∗(x∗, X, σˆ2)
}
,
where K∗(x∗, X, σˆ2) ∈ Rn with jth entry [K∗(x∗, X, σˆ2)]j =
∑M
s=1 σˆ
2
sks(x∗, xj) for j = 1, . . . , n. We
can also easily evaluate the estimated survival function, Sˆ at any time a since P (T∗ < a | z∗, x∗) is the
cumulative distribution function of a univariate normal distribution.
In studies collecting gene expression or other types of -omics data, there are often measured technical
confounders, e.g., the plate on which an RNA sample was stored. To address confounding in genome-wide
gene expression under (1), we propose to compute the kernel functions ks using the residuals from the
multivariate regression of gene expression on the measured technical confounders.
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To obtain reasonable initial values for our MC-EM algorithm with right-censored survival times, we sug-
gest first imputing the censored log-survival times using the inverse probability weighted mean-imputation
method proposed by Datta (2005).
4 Simulation studies
4.1 Data generating models
To create simulation scenarios similar to our motivating data example, we use the observed gene expression
data and clinical covariates of the 513 patients in the TCGA KIRC (kidney renal clear cell carcinoma)
dataset, and we simulate survival times for these patients. Specifically, we use the observed tumor stage and
age as clinical covariates, and use the observed expression of p = 20, 483 genes to generate survival times
from four distinct models. More information about how we prepared the TCGA KIRC dataset is given in
Section 5.1. For 500 independent replications, we generate n = 513 survival times and split the data into a
training and testing set of size 413 and 100 respectively. We then fit the model to the censored training data
and record the metrics described in Section 4.3. The data generating models we consider are:
Model 1: Gaussian process AFT model. Log-survival times are generated as a realization of the
Gaussian process accelerated failure time model:
T = Zβ + η + γ,
where γ ∼ Nn {0, 0.5In} and η ∼ Nn
{
0,K(X,σ2)
}
with K(X,σ2) defined below and β =
(6.1,−0.5,−1.2,−2.0,−1×10−5) where the columns of Z corresponds to the intercept, tumor stage
II, tumor stage III, tumor stage IV, and age in days.
Model 2: Normal-Logistic AFT model. Log-survival times are generated as a realization of the
normal-logistic accelerated failure time model,
T = Zβ + η + κ,
where κ = (κ1, . . . , κn)′ with each κi independent and identically distributed logistic distribution
such that E(κi) = 0 and Var(κi) = 0.5. Note that logistic distribution has much heavier tails than
normal distribution. As in Model 1, η ∼ Nn
{
0,K(X,σ2)
}
with K(X,σ2) defined below; and Z
and β are the same as in Model 1.
Model 3: Logistic-Logistic AFT model. Log-survival times are generated as a realization of the
logistic-logistic accelerated failure time model,
T = Zβ + ω + κ,
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where κ is generated in the same manner as in Model 2. To generate ω ∈ Rn, we generate v1, . . . , vn,
n independent copies of Vi ∼ Logistic where E(Vi) = 0 and Var(Vi) = 1 for i = 1, . . . , n.
Then, we set (ω1, . . . , ωn)′ = (v1, . . . , vn)′{K(X,σ2)}1/2 so that E(ωi) = 0 and Cov(ωi, ωj) =
[K(X,σ2)]i,j .
Model 4: Cox proportional hazards model. We generate survival times from the mixed-effects Cox
proportional hazards model with Gompertz baseline hazard (Bender et al., 2005). Let W = Z˜β + η
where β = (0.1, 0.3, 0.9, 9× 10−5) with columns of Z˜ corresponding to tumor stage II, tumor stage
III, tumor stage IV, and age in days, respectively; and let η ∼ Nn
{
0,K(X,σ2)
}
with K(X,σ2)
defined below. Then following Bender et al. (2005), we generated survival times as a realization of
Si =
1
α
log
[
1− α log(ui)
λexp(Wi)
]
, i = 1, . . . , n
where u1, . . . , un are n independent realizations of a Uniform(0, 1) random variable; and α =
pi(1200
√
6)−1 and λ = αexp(−.5772 − α1400) are chosen to mimic the survival distribution in
the real dataset with mean 1400 and standard deviation 1200.
For Models 1–4, the ith subject’s censoring time is drawn from an exponential distribution with mean{
exp
[
Qτi({Yj}nj=1)
]}−1
where Qc denotes the cth quantile and τi = .20, .50, .70, or .80 for subjects with
tumor stages I, II, III, or IV respectively. Between 62% - 63% of survival times are censored on average in
each of the four data generating models.
Models 2 – 4 illustrate our method’s performance under three different types of misspecification. In
Model 2, the error distribution is misspecified by our method, whereas in Model 3, both the genomic effect
and the error distribution are misspecified by our method. Under Model 4, the log-linearity of survival time
is violated.
For each of the four data generating models, we consider two variations of covariance functionK(X,σ2) :
Genome-wide kernel. We compute K(X,σ2) using a normalized radial basis function kernel based
on genome-wide gene-expression. Given xi ∈ Rp for i = 1, . . . , n, we compute
[K(X,σ2)]i,j = σ
2
Gk(xi, xj) ≡ σ2G exp
{ −‖xi − xj‖2
maxl,m (‖xl − xm‖2)
}
. (8)
In Models 1 – 3, we set σ2G = 3, and in Model 4, we set σ
2
G = 4.A histogram showing the off-diagonal
entries of (8) is displayed in Figure 2(b).
Pathway kernel. We compute K(X,σ2) as the sum of normalized radial basis function kernels as in
(8) based on a small number of genes meant to emulate gene-pathways:
[K(X,σ2)]i,j =
6∑
s=1
σ2sk(Dsxi, Dsxj), (i, j) ∈ {1, . . . , n} × {1, . . . , n} , (9)
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where for s = 1, . . . , 6, Ds ∈ Rp×p has 150, 150, 100, 100, 50, and 50 randomly positioned ones
on its diagonal and zeros in all other positions. Four of six σ2s are randomly assigned to be nonzero
and their magnitudes are drawn independently Uniform[0, 1] and normalized so that
∑6
s=1 σ
2
s = 3 in
Models 1 – 3, and
∑6
s=1 σ
2
s = 4 in Model 4.
The genome-wide kernel data generating model illustrates the performance of the competing methods when
effect sizes are small and abundant, i.e., genome-wide. The pathway-kernel data generating model is meant
to compare our method to those which perform variable selection or marginal screening since there will be
at most five hundred genes that affect the survival time distribution.
4.2 Methods
In their review of methods for predicting survival time based on gene expression, Van Wieringen et al. (2009)
concluded that among the tree-based ensemble methods and regularized Cox proportional hazard models
they compared, the L2-penalized Cox proportional hazards model performed as well or better than the other
methods. For this reason, we exclude tree-based ensemble methods from our comparisons, but include the
L1 and L2-penalized Cox-proportional hazards model using genome-wide gene expression, tumor stage,
and age as covariates. We do not penalize coefficients corresponding to tumor stage or age in either model
and select tuning parameters using ten-fold cross-validation. We also consider L1 and L2-penalized Cox
proportional hazards models using a pre-screened gene sets, which we call L∗1 and L∗2. When the data
generating model uses the genome-wide kernel, the screening method retains genes that are significantly
associated with survival with false discovery rate below 0.10. When the data generating model uses the
pathway kernels, the screening method retains the six-hundred genes that are used to construct the pathway
kernels, i.e., assuming an oracle screening method.
We use two variations of our Gaussian process accelerated failure time model. The versions denoted
GPR:K and GPR:M correspond to the genome-wide kernel and pathway kernels, respectively. For GPR:K,
we use (8) as the lone candidate kernel. For GPR:M, we use seven candidate kernels: the six pathway kernels
from (9), and a genome-wide kernel which is similar to (8), except it uses all genes not used in any of the
pathway kernels. When the data-generating model uses the genome-wide kernel, the six pathway kernels are
computed from 600 randomly selected genes. When the data generating model uses the pathway-kernels,
GPR:M includes the true pathway-kernels as candidates.
To illustrate the benefit of our imputation procedure, which jointly imputes censored survival times
and estimates model parameters, we also compare our method to two versions of the Gaussian process
accelerated failure time model that imputes survival times using the inverse probability weighted mean
imputation procedure of Datta (2005). These approaches, which we call LMM:K and LMM:M, fit variations
of (1) using the MM-algorithm from Zhou et al. (2015), treating the imputed survival times as fixed.
Finally, we also consider two variations of the mixed-effects Cox proportional hazards model used in
Zhu et al. (2017). These versions are denoted ME-Cox:K and ME-Cox:M and use the same candidate
kernels as GPR:K and GPR:M, respectively.
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4.3 Performance metrics
As noted in Van Wieringen et al. (2009), there is no consensus on which metric to use for evaluating the
accuracy of prediction in survival analysis. For this reason, we use three different metrics. The first metric is
based on the C-index measurement proposed by Uno et al. (2011). Given Sˆ, the nv predicted survival times
or risk scores for the testing set, we define the C-index as:∑nv
i=1
∑nv
j=1 δi{Hˆ(Si)}−21(Si < Sj , Si < τ)1(C(Sˆi) > C(Sˆj))∑nv
i=1
∑nv
j=1 δi{Hˆ(Si)}−21(Si < Sj , Si < τ)
,
where C : R → R maps a predicted survival time to the risk score scale, 1(·) is the indicator function, τ is
the study length, and Hˆ(·) is the Kaplan-Meier estimator of the censoring distribution.
The second metric we use is the integrated Brier score. While C-index evaluates the prediction of
accuracy in terms of relative order of survival times, the Brier score quantifies the accuracy of survival time
function estimate at time t:
B(t) = nv
−1
nv∑
i=1
{
[Sˆ(t|zi, xi)]2 min {1(Si ≤ t), δi} {Hˆ(Si)}−1 + [1− Sˆ(t|zi, xi)]21(Si > t){Hˆ(Si)}−1
}
,
where Sˆ(t|zi, xi) is the estimated survival function for the ith subject in the testing data evaluated at time t.
The integrated Brier score we use is
BS = τ−1
∫ τ
0
B(t)dt.
The third metric we use is integrated AUC based on the sensitivity and specificity measures defined by
Uno et al. (2007). This AUC-based metric measures the accuracy of t-year survival prediction. We use the
function AUC.uno from the R package SurvAUC in our implementation.
In the simulation study, we have access to the true survival times for the entire testing set, so Hˆ(Yj) = 1
and δj = 1 for all j in the testing set. Thus, in the simulation study, we set τ equal to the largest survival
time in the testing data. In the real data analyses, we estimate Hˆ using the Kaplan-Meier estimator and set
τ equal to the second largest observed survival time in the testing data.
4.4 Results
Simulation results for 500 independent replications are displayed in Table 1. To compare methods, for each
replication we record the ratio of each method’s performance to the best performance amongst all methods.
For C-index and integrated-AUC, a ratio less than one indicates worse performance, whereas for integrated
Brier score, a ratio great than one indicates worse performance.
Under Models 1 – 3, our proposed methods GPR:K and GPR:M were the best amongst the competing
methods in terms of integrated Brier score. For integrated AUC and C-index, the version of our method
with correctly specific covariance was best. Under Model 4, our method performs poorly relative to the
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Covariance Metric
Regularized Cox ME Cox GPR LMM
Scale
L1 L
∗
1 L2 L
∗
2 K M K M K M
Model 1
Genome-wide
Brier 1.175 1.166 1.153 1.148 1.180 1.165 1.012 1.021 1.140 1.140 0.050
AUC 0.964 0.964 0.983 0.984 0.945 0.943 0.988 0.983 0.975 0.969 0.796
C-index 0.971 0.971 0.979 0.980 0.954 0.953 0.992 0.988 0.980 0.975 0.709
Pathway
Brier 1.177 1.173 1.157 1.162 1.186 1.169 1.028 1.015 1.164 1.156 0.050
AUC 0.953 0.959 0.972 0.978 0.931 0.936 0.977 0.990 0.963 0.976 0.804
C-index 0.960 0.965 0.968 0.973 0.940 0.945 0.980 0.992 0.968 0.979 0.716
Model 2
Genome-wide
Brier 1.168 1.156 1.145 1.137 1.169 1.155 1.013 1.021 1.133 1.134 0.048
AUC 0.961 0.961 0.984 0.982 0.946 0.945 0.986 0.981 0.972 0.966 0.793
C-index 0.968 0.968 0.979 0.979 0.955 0.955 0.990 0.985 0.978 0.972 0.708
Pathway
Brier 1.179 1.177 1.160 1.165 1.183 1.169 1.030 1.016 1.161 1.153 0.049
AUC 0.954 0.958 0.974 0.978 0.933 0.938 0.976 0.990 0.962 0.974 0.807
C-index 0.960 0.964 0.969 0.973 0.942 0.946 0.980 0.992 0.967 0.978 0.719
Model 3
Genome-wide
Brier 1.179 1.168 1.158 1.150 1.180 1.165 1.020 1.030 1.127 1.124 0.046
AUC 0.963 0.964 0.984 0.984 0.942 0.942 0.988 0.982 0.966 0.973 0.794
C-index 0.971 0.971 0.981 0.981 0.952 0.951 0.991 0.986 0.972 0.978 0.711
Pathway
Brier 1.186 1.184 1.166 1.172 1.199 1.181 1.028 1.019 1.149 1.142 0.045
AUC 0.957 0.961 0.975 0.980 0.935 0.938 0.980 0.991 0.966 0.975 0.805
C-index 0.963 0.966 0.970 0.974 0.943 0.946 0.983 0.992 0.970 0.977 0.720
Model 4
Genome-wide
Brier 1.056 1.065 1.043 1.052 1.068 1.060 1.150 1.157 1.077 1.079 0.093
AUC 0.971 0.968 0.988 0.983 0.961 0.961 0.980 0.977 0.972 0.967 0.754
C-index 0.979 0.977 0.985 0.982 0.970 0.971 0.986 0.984 0.979 0.975 0.678
Pathway
Brier 1.064 1.062 1.049 1.050 1.077 1.069 1.145 1.142 1.091 1.082 0.092
AUC 0.966 0.967 0.983 0.986 0.955 0.957 0.975 0.980 0.965 0.968 0.759
C-index 0.974 0.976 0.981 0.983 0.966 0.967 0.981 0.987 0.974 0.976 0.682
Table 1: Average relative performance for five hundred independent replications under the four models.
Relative performance is defined as the ratio of each method’s error to the best amongst all the competing
methods, so that a relative performance of one indicates that the method performed best amongst all the
methods. For integrated AUC and C-index, a relative error less than one indicates worse performance,
whereas for integrated Brier score, a relative error of greater than one indicates worse performance. Cells
highlighted in dark grey indicate a relative performance significantly better than all other methods. Cells
highlighted in light grey indicate the best average relative performance, but one not significantly better than
all other methods. The scale column displays the mean of the best method’s metric across the five hundred
replications.
Cox proportional hazards models and the IPW-imputed version of our method in terms of integrated Brier
score and AUC, but performs nearly as well or better than the Cox proportional hazards models in terms of
C-index. This may imply that the Cox model could provide more accurate estimates of the survival function,
but less accurate prediction of relative order.
It is also important to analyze the performance of GPR:K when the covariance K(X,σ2) is generated
from the data generating models using pathway kernels. In general, GPR:K, which uses genome-wide gene
expression, performs only slightly worse than GPR:M in terms of C-index and integrated Brier score, and
is often similar to the L2-penalized Cox proportional hazards model with screening in terms of integrated
AUC. Thus, even though only approximately 2.5% of genes actually contribute to the genomic effect under
the pathway-based data generating model, using genome-wide gene-expression does not seem to degrade
prediction accuracy drastically.
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Figure 2: (a) Correlations between the imputed log-survival time and true log-survival time for the censored
outcomes in the training sets. (b) A histogram showing the off-diagonal entries of the normalized radial
basis kernel using genome-wide gene expression.
In Figure 2a, we display boxplots showing the correlation between the true log survival time and the
imputed log survival for the censored training data. The method GPR:I, which fits (1) assuming G = 0,
performs worse than either GPR:K or GPR:M, all of which perform better substantially better than the IPW
mean imputation procedure of Datta (2005), denoted IPW-MI. This partly explains the relative advantage
of GPR over LMM.
5 KIRC data analysis
5.1 Data preparation
We downloaded demographic/clinical data as well as RNA-seq data (from workflow HTSeq - Counts) of
TCGA KIRC patients from NCI Genomic Data Commons (http://portal.gdc.cancer.gov/). Data were pre-
processed in the following steps. We omitted patients for whom gene expression was measured on a plate
with fewer than ten patients and patients who did not have a measured tumor stage. To filter out genes with
relatively low expression in most samples, we use genes whose 75% percentile read-count was greater than
20. For the 20,428 genes with sufficient read counts, the expression measurement xik, i.e., the expression for
the ith individual and kth gene, is log10[(tik + 1)/qi,0.75] where qi,0.75 is the 75th percentile of read counts
for the ith individual and tik is the read count for the ith individual’s kth gene. For the resulting dataset
consisting of 513 patients with gene expression measured on 20,428 genes, we found that tumor stage, age,
and sequencing plate had significant marginal associations with survival under the Cox proportional hazards
model. Following Zhu et al. (2017), we also include gender as a covariate.
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Figure 3: (a) - (c) Results from 500 independent training/testing splits. Each point represents the method’s
performance relative to the best performing method within one replication. For (a) and (b), a relative C-
index or relative integrated AUC less than one indicates worse performance. For (c), a relative Brier score
of greater than one indicates a worse performance. (d) Estimated variance components for each of the
candidate kernel in GPR:M.
5.2 Pathway-based candidate kernels
Following our simulation studies, we propose to use the normalized radial basis kernel k(·, ·) to define the
kernel function K. We consider multiple variations of our method: the genome-wide version, GPR:K,
which uses the normalized radial basis kernel based on genome-wide gene expression; and the pathway
version, GPR:M, which uses kernels computed using genes from individual pathways and a genome-wide
gene expression kernel computed using all genes not included in any of the pathways.
We selected six pathways based on the existing knowledge of the molecular characteristics of kidney
renal clear cell carcinoma (KIRC). The PI3K/AKT/mTOR pathway (PI3K) was selected because genes in
this pathway were recurrently mutated in KIRC patients (Cancer Genome Atlas Research Network, 2013).
Because KIRC is characterized by a disordered metabolism, we also selected four pathways associated with
metabolic function: glycolysis and gluconeogenesis (Glyc/Gluc), metabolism of fatty acids (Fatty acid),
pentose phosphate pathway (Pent/Phos), and citrate cycle pathway (Citrate cycle). The genes belonging to
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three pathways PI3K, Glyc/Gluc, and Fatty acid were obtained from Molecular Signatures Database hosted
by the Broad Institute http://software.broadinstitute.org/gsea/msigdb, and the genes of pathways Pent/Phos
and Citrate cycle were obtained from Pathway Commons http://www.pathwaycommons.org/. Finally, we
included the pathway/gene-set, which includes genes that are expressed in different immune cell types and
are used in the CIBERSORT software package (Newman et al., 2015) (CSORT). We included this gene set
to capture potential immune-related information because previous studies have associated long survival time
in KIRC patients with immune infiltration (Escudier, 2012).
We use our proposed confounder adjustment approach to adjust for the potential confounding of se-
quencing plate ID, age, and tumor stage. Specifically, we fit the multivariate regression of gene expression
on sequencing plate ID, tumor stage, age, and gender, and compute the candidate kernels using the residuals.
We found this adjustment had a minimal effect on survival time prediction accuracy relative to the version
without confounding adjustment.
5.3 Analyses and results
Following the setup of our simulation studies, we randomly split the data into training and testing sets of size
413 and 100, respectively, for 500 independent replications. To compare the performance across methods,
we use the same metrics defined in Section 4.3. Unlike our simulation studies, the test set contains censored
survival times, so when computing the C-index and integrated Brier score, we estimate Hˆ using the Kaplan-
Meier estimator on the testing data. The best C-index average was 0.746, the best integrated AUC average
was 0.794, and the best integrated Brier score average was 0.155.
We display results for a subset of the competitors considered in our simulation studies in Figure 3.
Both variations of our proposed method, GPR:K and GPR:M, significantly outperformed the competitors
across all three metrics. We noticed that the genome-wide version of our estimator tended to outperform
the estimator which used pathway-based kernels. To further illustrate the contribution of each variance
component in pathway-based analysis, we display boxplots of the relative magnitudes of the estimated
variance components across the five hundred replications (Figure 3(d)). We found that genome-wide effects
accounted for approximately 70% of variability in log-survival time, whereas random noise accounted for
25%-30%. Of the considered pathways, the pentose phosphate and fatty acid metabolism pathways were
most frequently estimated to be away from zero, with the fatty acid metabolism pathway contributing nearly
50% of variability in a small number of replications. Overall these results suggest that these few pathways do
not make a significant contribution to survival time prediction and most information are from genome-wide
gene expression.
6 Discussion
In this paper, we propose a new method to predict survival time using genome-wide gene expression data.
Using the framework of Gaussian process regression, we develop a flexible and computationally efficient
16
algorithm to perform two tasks: to impute censored survival time and to estimate the parameters of the
model. We model the covariance structure of the log-survival time using one or more kernels defined using
gene expression data. In both simulations and real data analyses, we define multiple kernels using gene
expression from multiple pathways, though in practice, these kernels can be defined using the same set of
genes with different definitions of distance/similarities, or they can be defined based on multiple types of
-omic data. Although we have developed our method for survival time prediction, it can be used or extended
for other outcomes with certain patterns of missing data.
There are several directions to improve or extend our method. When the number of kernels is large, e.g.,
tens or hundreds of kernels, some regularization or penalty should be applied on the weight of each kernel.
Although our simulations studies have demonstrated that our method is not sensitive to deviation from
Gaussian distribution assumption, it is desirable to develop more robust non-parametric or semi-parametric
approaches (Zeng and Lin, 2007).
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